Yes, you’ve chosen hATTR amyloidosis, which is the most likely
diagnosis for this patient
The next step for this patient is genetic testing to confirm the diagnosis. Evidence of heart failure, in combination with low QRS voltage on ECG, left ventricular wall thickening, and myocardial speckling on echocardiogram, are findings suggestive of hATTR amyloidosis. Additionally, the onset of paresthesia and neuropathic pain may be due to peripheral neuropathy. Myocardial uptake of the 99mTc-PYP tracer indicates the presence of amyloid, and this result, combined with the lack of monoclonal protein in serum and urine, can rule out AL amyloidosis. Furthermore, family history of death from early onset heart failure suggests a hereditary component of disease.1,2
Now is the time to send this patient for genetic testing to confirm the diagnosis of hATTR amyloidosis.
Alnylam Act® is one option for genetic testing, which can help confirm the presence of a genetic mutation.
Alnylam is sponsoring no-charge third-party genetic testing and counseling for individuals who may carry gene mutations known to be associated with hereditary ATTR (hATTR) amyloidosis. While Alnylam provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient identifiable information. Alnylam receives contact information for healthcare professionals who use this program. Genetic testing is available in the U.S. and Canada. Genetic counseling is only available in the U.S. Healthcare professionals and patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use or support any Alnylam product.
Want to send a patient for genetic testing?
Download the Alnylam Act® order form now.
- Dharmarajan K, Maurer MS. J Am Geriatr Soc. 2012;60(4):765-774.
- Gillmore JD, Maurer MS, Falk RH, et al. Circulation. 2016;133(24):2404-2412.